FIELD: medicine； pharmaceuticals.SUBSTANCE: group of inventions refers to pharmaceutical industry, namely to agents inhibiting activity of D-amino acid oxidase. Composition for inhibiting activity of D-amino acid oxidase (DAAO), containing (i) tannic acid or its pharmaceutically acceptable salt and (ii) and a pharmaceutically acceptable carrier, wherein tannic acid contains 4, 5, 6, 7, 8, 9, 10, 11 or 12 galloid groups and where tannic acid is at least 90 % by weight of all tannic acids contained in composition. Method of treating a disease associated with D-amino acid oxidase (DAAO) activity, which is obesity, hyperlipidemia, diabetes or central nervous system (CNS) disorder, involving administering to an individual in need thereof an effective amount of the composition. Method of producing a tannic acid composition comprising: (i) obtaining oak nuts； (ii) grinding oak nuts to produce oak nuts powder； (iii) extraction of oak nuts powder with a first solvent to produce a first extract of tannic acid； and (iv) contacting the extract of tannic acid with carbon, CaSO4, MgSO4 or with their combinations to remove substances absorbed on carbon or deposited with CaSO4 or MgSO4 to obtain a first tannic composition, where the first solvent is acetone, acetonitrile, methyl ethyl ketone, ethyl acetate, ethanol, isopropanol, tetrahydrofuran, 1,4-dioxane, hexane or a combination thereof.EFFECT: composition described above has higher DAAO inhibition activity.40 cl, 23 dwg, 8 tbl, 8 exГруппа изобретений относится к фармацевтической промышленности, а именно к средствам, ингибирующим активность оксидазы D-аминокислоты. Композиция для ингибирования активности оксидазы D-аминокислоты (DAAO), содержащая (i) дубильную кислоту или ее фармацевтически приемлемую соль и (ii) и фармацевтически приемлемый носитель, где дубильная кислота содержит 4,5,6,7,8,9,10,11 или 12 галлоильных групп и где дубильная кислота составляет по меньшей мере 90% по массе всех дубильных кислот, содержащихся в к
